Elie Dolgin’s recent article in Nature Biotechnology explains why the apparent failure of the first senolytic drug to enter clinical trials is far from being a refutation of the senolytic hypothesis, and reviews the growing arsenal of other senolytics currently in development – including work by SRF’s Dr. Amit Sharma and SRF-supported startup Oisín Biotechnologies.
Send In The Senolytics
- By SRF
- November 17, 2020
- 9:50 am
Elie Dolgin's recent article in Nature Biotechnology explains why the failure of the first senolytic drug to enter clinical trials is far from being a refutation of the senolytic hypothesis, and reviews the growing arsenal of other senolytics currently in development - including work by SRF's Dr. Amit Sharma and SRF-supported startup Oisín Biotechnologies.

- By SRF
- November 17, 2020
- 9:50 am
Recent Posts:
A Message from the SRF Board of Directors
SRF April 15, 2022 8:11 pm
New Peer-Reviewed Paper from SENS Research Foundation Reports a Better Method to Study How Immune Cells Seek and Destroy Senescent Cells
Michael Rae April 12, 2022 2:02 am
We are thrilled to announce the expansion of our Research Center
SRF April 1, 2022 11:25 pm
Michael Rae and Dr. Robert Rodgers discuss Parkinson’s and aging
Michael Rae January 24, 2022 5:32 am
SENS Research Foundation & Underdog Pharmaceuticals jointly awarded $252,000 NIA research grant
SRF December 8, 2021 10:32 pm
SRF’s researchers presenting our work at Indian biosciences conferences
SRF November 30, 2021 12:26 am
Longevity Science Foundation’s $1 billion, 10 year distribution shows shift in attitudes since SRF inception
SRF October 26, 2021 7:41 am
Congratulations to our long-time collaborators: the Buck Institute, Judith Campisi and team for the new NIH grant.
SRF October 20, 2021 8:29 pm
NIA Reports Senolytics Show Potential to Protect Against Coronavirus in Older Mice
SRF October 7, 2021 10:52 pm
SENS Research Foundation wishes you Happy International Longevity Day and Longevity Month!
SRF October 1, 2021 9:37 pm